Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes.
Nicola S MeagherKylie L GorringeMatthew J WakefieldAdelyn BolithonChi Nam Ignatius PangDerek S ChiuMichael S AnglesioKylie-Ann MallittJennifer Anne DohertyHolly R HarrisJoellen M SchildkrautAndrew BerchuckKara L Cushing-HaugenKsenia ChezarAngela ChouAdeline TanJennifer AlsopEllen L BarlowMatthias W BeckmannJessica BorosDavid D L BowtellAlison H BrandJames D BrentonIan G CampbellDane CheasleyJoshua G CohenCezary CybulskiEsther ElishaevRamona ErberRhonda FarrellAnna Katharina FischerZhuxuan FuC Blake GilksAnthony J GillCharlie GourleyMarcel GrubePaul HarnettArndt HartmannAnusha HettiaratchiClaus K HøgdallTomasz HuzarskiAnna JakubowskaMercedes Jimenez-LinanCatherine J KennedyByoung Gie KimJae-Weon KimJae-Hoon KimKayla KlettJennifer M KoziakTiffany LaiAngela LaslavicJenny LesterYee LeungNa LiWinston LiauwBelle W X LimAnna LinderJan A LubińskiSakshi MahaleConstantina MateoiuSimone McInernyJanusz MenkiszakParham MinooSuzana MittelstadtDavid L MorrisSandra OrsulicSang-Yoon ParkCeleste Leigh PearceJohn V PearsonMalcolm C PikeCarmel M QuinnGanendra Raj MohanJian Yu RaoMarjorie J RigganMatthias RuebnerStuart SalfingerClare L ScottMitul ShahHelen SteedColin J R StewartDeepak N SubramanianSoseul SungKatrina TangPaul TimpsonRobyn L WardRebekka WiedenhoeferHeather ThornePaul Andrew CohenPhilip J CrowePeter Andreas FaschingJacek GronwaldNicholas J HawkinsEstrid V S HøgdallDavid G HuntsmanPaul A JamesBeth Y KarlanLinda E KelemenStefan KommossGottfried E KonecnyFrancesmary ModugnoSue-Kyung ParkAnnette StaeblerKarin SundfeltAnna H WuAline TalhoukPaul D P PharoahLyndal AndersonAnna De FazioMartin KoebelMichael L FriedlanderSusan J RamusPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
An infiltrative growth pattern infers poor prognosis within 2-years from diagnosis and may help select Stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confer an adverse prognosis and is upregulated in the infiltrative subtype which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies.